



Estrogen receptor activation contributes to RNF146 expression and neuroprotection in Parkinson's disease models


SUPPLEMENTARY MATERIALS




Supplementary Figure 1: (A) Cell Counting Kit-8 (CCK8) viability assay demonstrating that GFP-RNF146 expression and PARP inhibition both increase cell survival after stimulation with H₂O₂ (1 mM). SH-SY5Y cells were transfected with constructs driving the expression of GFP or GFP-RNF146 for 24 hrs and then treated for 24 hrs with H₂O₂. The PARP inhibitor 3AB (10 uM) was added to SH-SY5Y cells 4 hrs before toxin treatment (*n* = 6). (B) Trypan blue exclusion viability assay in SH-SY5Y cells treated with increasing concentrations of 6-OHDA (10, 50, 100, and 200 uM) for 24 hrs (*n* = 6). (C) Trypan blue exclusion viability assay in SH-SY5Y cells treated with increasing concentrations of rotenone (1, 5, 10, 20, and 30 uM) for 24 hrs (*n* = 6). (D) Expression levels of RNF146 and AIMP2 in SH-SY5Y cells transfected with the indicated combinations of GFP-RNF146 and GFP-AIMP2. Western blotting was carried out using the designated antibodies. β-actin serves as a loading control.




Supplementary Figure 2: (A) Schematic illustration of the experimental schedule for H₂O₂ preconditioning (100 uM, 10 min) in SH-SY5Y cells followed by treatment with toxic concentrations of H₂O₂ and cell viability assessment. (B) Trypan blue exclusion viability assay in SH-SY5Y cells challenged with 1 mM H₂O₂ for 24 hrs with or without low-dose H₂O₂ preconditioning ($n = 6$). Data are expressed as mean \pm SEM. *** $P < 0.001$, ANOVA test followed by Tukey's post hoc analysis.




Supplementary Figure 3: (A) Scatter plot of the Z' factors of the 96-well plates used in the high-throughput luciferase screen. The Z' factor was calculated for each plate using the means (M) and standard deviations (SD) from the negative (DMSO) and positive (H₂O₂ preconditioning (100 uM, 10 min)) controls. $Z' = 1 - 3(SD_{CCCP+SDDMSO}) / (M_{CCCP} - M_{DMSO})$. (B) Chemical structures of the natural compounds (liquiritigenin, chlorogenic acid, rhododendrin, piperlonguminine) that increased RNF146 promoter activity in the luciferase assay.




Supplementary Figure 4: (A) UV spectrum, HPLC-ELSD spectrum, and chemical structure of liquiritigenin extracted from *Glycyrrhiza uralensis*. (B, C) ^1H - and ^{13}C -NMR spectra of purified liquiritigenin demonstrating its chemical structure. (D) Quantification of relative RNF146 messenger RNA expression in SH-SY5Y cells treated with DMSO or liquiritigenin (37 hrs) at the indicated concentrations. GAPDH was used as an internal loading control ($n = 3$). (E) Immunoblot analysis of RNF146 levels in SH-SY5Y cells treated with the indicated concentrations of liquiritigenin for 37 hrs. Quantification of relative RNF146 expression levels (normalized to those of β -actin) from panel A ($n = 3$). (F) Quantification of relative RNF146 mRNA levels in SH-SY5Y cells treated with the indicated combinations of liquiritigenin (10 μM , 48 hrs) and tamoxifen (1 μM , 8 hrs). Values are normalized to those of GAPDH ($n = 3$). (G) Immunoblots of RNF146 in lysates from SH-SY5Y cells treated with estradiol (10 nM) for the indicated periods of time. β -actin serves as an internal loading control. Quantification of relative RNF146 expression levels. Values are normalized to those of β -actin in panel A ($n = 3$, bottom panel). (H) Specific knockout of ER α by CRISPR-cas9 in SH-SY5Y cells determined by western blot using the indicated antibodies. ER α was used as a negative control. (I) Illustration of RNF146 promoter structure and potential ER α binding motif. Approximate binding sites for primer sets are indicated by arrows. Red arrows (F: -1848 to -1828; R: -1620 to -1579 bp from transcription start site of RNF146) for putative ER α binding motif; Blue arrows (F: -487 to -445; R: -318 to -299 bp from transcription start site of RNF146) for negative control within RNF146 promoter.



Supplementary Figure 5: (A) Trypan blue exclusion viability assay in SH-SY5Y cells treated for 24 hrs with increasing concentrations of liquiritigenin ($n = 6$). (B) Assessment of relative intracellular ATP levels in SH-SY5Y cells challenged with H_2O_2 (1 mM, 24 hrs) following pretreatment with liquiritigenin (10 μM , 48 hrs) or DMSO vehicle as a control ($n = 6$). (C) Expression of RNF146 in mouse primary cortical neuron culture treated with DMSO or liquiritigenin determined by western blots. Quantification of relative RNF146 expression in liquiritigenin (10 μM , 37 hrs) treated group as compared to DMSO control ($n = 9$, right panel). (D) CCK8 viability assay in mouse cortical neurons pretreated with liquiritigenin (10 μM , 37 hrs) and challenged with H_2O_2 (100 μM , 24 hrs). (E) Spectrophotometry analysis of CCK8 viability assay for panel D ($n = 8$ per group). (F) Trypan blue exclusion viability assay in SH-SY5Y cells demonstrating the protective effect of liquiritigenin (10 μM , 48 hrs) against 6-OHDA (70 μM , 24 hrs) and rotenone (20 μM , 24 hrs)-induced cell death ($n = 6$). (G) Trypan blue exclusion viability assay in SH-SY5Y cells demonstrating the protective effect of liquiritigenin (10 μM) against AIMP2 overexpression (30 hrs) ($n = 6$). (H) Immunoblots of PAR, PARP1, RNF146, and FLAG-AIMP2 in lysates from SH-SY5Y cells transiently transfected with FLAG-AIMP2 or mock (60 hrs) and treated with liquiritigenin (10 μM , 37 hrs). β -actin serves as an internal loading control. (I) Quantification of relative PAR-conjugated proteins and RNF146 expression levels in the indicated experimental groups. Values are normalized to those of β -actin ($n = 3$).



Supplementary Figure 6: (A) Representative western blots of RNF146 expression in SH-SY5Y cells transfected with shRNA targeting RNF146 or DsRed as a control. β -actin serves as a loading control. Quantification of relative RNF146 expression in SH-SY5Y cells transfected with shRNA targeting RNF146 or DsRed as a control ($n = 3$, bottom panel). Values are normalized to those of β -actin. (B) Assessment of relative intracellular ATP levels in SH-SY5Y cells transfected with shRNA directed against RNF146 (64 hrs, $n = 6$) and challenged with H₂O₂ (1 mM, 16 hrs) with or without pretreatment with liquiritigenin (10 μ M, 40 hrs) or DMSO vehicle. shDsRed was used as an shRNA transfection control.



Supplementary Figure 7: Relative expression levels of RNF146 mRNA in the indicated brain subregions from 2-month-old mice treated with DMSO or liquiritigenin (i.p., 10 mg/kg/day, 3 days) determined by realtime quantitative PCR using specific primers for mouse RNF146 ($n = 4$ mice). GAPDH was used as an internal loading control.